JP2019524894A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524894A5
JP2019524894A5 JP2019530540A JP2019530540A JP2019524894A5 JP 2019524894 A5 JP2019524894 A5 JP 2019524894A5 JP 2019530540 A JP2019530540 A JP 2019530540A JP 2019530540 A JP2019530540 A JP 2019530540A JP 2019524894 A5 JP2019524894 A5 JP 2019524894A5
Authority
JP
Japan
Prior art keywords
morufikku
motomeko
powder
ray diffraction
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524894A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/070950 external-priority patent/WO2018033631A1/en
Publication of JP2019524894A publication Critical patent/JP2019524894A/ja
Publication of JP2019524894A5 publication Critical patent/JP2019524894A5/ja
Priority to JP2022063985A priority Critical patent/JP2022101588A/ja
Pending legal-status Critical Current

Links

JP2019530540A 2016-08-19 2017-08-18 マリゾミブのモルフィック形態およびその使用 Pending JP2019524894A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022063985A JP2022101588A (ja) 2016-08-19 2022-04-07 マリゾミブのモルフィック形態およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377156P 2016-08-19 2016-08-19
US62/377,156 2016-08-19
PCT/EP2017/070950 WO2018033631A1 (en) 2016-08-19 2017-08-18 Morphic forms of marizomib and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022063985A Division JP2022101588A (ja) 2016-08-19 2022-04-07 マリゾミブのモルフィック形態およびその使用

Publications (2)

Publication Number Publication Date
JP2019524894A JP2019524894A (ja) 2019-09-05
JP2019524894A5 true JP2019524894A5 (enExample) 2020-08-13

Family

ID=59745883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530540A Pending JP2019524894A (ja) 2016-08-19 2017-08-18 マリゾミブのモルフィック形態およびその使用
JP2022063985A Pending JP2022101588A (ja) 2016-08-19 2022-04-07 マリゾミブのモルフィック形態およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022063985A Pending JP2022101588A (ja) 2016-08-19 2022-04-07 マリゾミブのモルフィック形態およびその使用

Country Status (4)

Country Link
US (3) US10703760B2 (enExample)
EP (1) EP3500576A1 (enExample)
JP (2) JP2019524894A (enExample)
WO (1) WO2018033631A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3500576A1 (en) 2016-08-19 2019-06-26 Celgene International II Sàrl Morphic forms of marizomib and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402045T3 (es) 2000-11-16 2013-04-26 The Regents Of The University Of California Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación
US7179834B2 (en) 2002-06-24 2007-02-20 The Regents Of The University Of California Salinosporamides and methods for use thereof
AU2003272270A1 (en) * 2003-02-28 2004-09-28 The Regents Of The University Of Michigan Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
NZ544588A (en) 2003-06-20 2010-06-25 Nereus Pharmaceuticals Inc Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
EP2266988A1 (en) * 2004-04-30 2010-12-29 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7803786B2 (en) * 2004-06-17 2010-09-28 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
CN103230394B (zh) 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 治疗肿瘤性疾病的化合物及其用途
WO2006124902A2 (en) 2005-05-16 2006-11-23 Sloan-Kettering Institute For Cancer Research Synthesis of salinosporamide a and analogues thereof
US7572606B1 (en) 2005-09-09 2009-08-11 Nereus Pharmaceuticals, Inc. Biosyntheses of salinosporamide A and its analogs and related methods of making salinosporamide A and its analogs
AU2006311734A1 (en) 2005-11-04 2007-05-18 Nereus Pharmaceuticals Methods of sensitizing cancer to therapy-induced cytotoxicity
MX2008012847A (es) 2006-04-06 2008-10-13 Nereus Pharmaceuticals Inc Sintesis total de salinosporamida a y analogos de la misma.
WO2007120801A2 (en) 2006-04-13 2007-10-25 Nereus Pharmaceuticals, Inc. Fermentation method
WO2007130404A1 (en) 2006-05-03 2007-11-15 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for the treatment of lung cancer
US8986971B2 (en) 2006-09-22 2015-03-24 Triphase Research And Development I Corp. Salt formulations for the fermentation of marine microorganisms
WO2008095195A2 (en) 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
WO2008124699A1 (en) 2007-04-06 2008-10-16 Nereus Pharmaceuticals, Inc. A method of using proteasome inhibitors in combination with histone deacetylase inhibitors to treat cancer
US20080280968A1 (en) 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
CN102015721A (zh) 2008-03-07 2011-04-13 尼瑞斯药品公司 Salinosporamide a及其类似物的全合成
JP2011519975A (ja) 2008-05-12 2011-07-14 ネレアス ファーマシューティカルズ インコーポレイテッド プロテアソーム阻害剤としてのサリノスポラミド誘導体
WO2017210463A1 (en) 2016-06-01 2017-12-07 Celgene Tri A Holdings Ltd. Use of marizomib for the treatment of central nervous system (cns) cancers
EP3500576A1 (en) 2016-08-19 2019-06-26 Celgene International II Sàrl Morphic forms of marizomib and uses thereof
US20200085789A1 (en) 2017-03-14 2020-03-19 Celgene International Ii Sàrl Use of a proteasome inhibitor for the treatment of central nervous system (cns) cancers

Similar Documents

Publication Publication Date Title
JP2010539237A5 (enExample)
JP2019514863A5 (enExample)
Garudachari et al. Click chemistry approach: Regioselective one-pot synthesis of some new 8-trifluoromethylquinoline based 1, 2, 3-triazoles as potent antimicrobial agents
JP2018532719A5 (enExample)
JP2018520178A5 (enExample)
HRP20201420T1 (hr) Derivati žučne kiseline kao agonisti fxr/tgr5
RU2017121457A (ru) Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
JP2016121196A5 (enExample)
JP2019505533A5 (enExample)
JP2011513485A5 (enExample)
JP2020500931A5 (enExample)
JP2007532560A5 (enExample)
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
JP2018510914A5 (enExample)
JP2014510746A5 (enExample)
WO2018136001A1 (en) Process for preparing apalutamide
WO2011033307A1 (en) Nilotinib dihydrochloride salt
WO2013175506A2 (en) Process for sorafenib tosylate polymorph iii
JP2018534243A5 (enExample)
JP2019524894A5 (enExample)
CN103788013A (zh) 一种2-芳基苯并噻唑化合物的合成方法
CN107698574B (zh) 一种高纯度阿瑞匹坦的精制制备工艺
KR102588109B1 (ko) 암 치료에 유용한 1-(사이클로) 알킬 피리딘-2-온의 트리사이클릭 융합 유도체
CN101914056B (zh) 一种n-烷基取代四氢咔唑酮衍生物的制备方法
CN103965185B (zh) 含有噻唑基和酯基的1,5-苯并二氮杂卓化合物及其应用